Drug
VY Aadc01
VY Aadc01: highest development phase Phase 1, developed by Neurocrine Biosciences. 2 trial records tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Neurocrine Biosciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| VY-AADC01 NCT01973543 | Phase 1 | Parkinson's Disease |
| VY-AADC01 NCT03065192 | Phase 1 | Idiopathic Parkinson's Disease |
Latest
No recent events.
Follow VY Aadc01 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.